GLENWOOD, Ill., Dec. 19, 2016 /PRNewswire/ -- Landauer, Inc.
(NYSE: LDR), a recognized leader in personal and environmental
radiation measurement and monitoring and outsourced medical physics
services, today issued the following statement in response to
Gilead Capital LP's ("Gilead") nomination of three candidates,
including Gilead's Chief Investment Officer and Managing Partner,
Jeffrey A. Strong, for election to
Landauer's Board of Directors at the Company's 2017 Annual Meeting
of Stockholders.
"Landauer's Board is open to constructive input from all
stockholders and has been engaged in an ongoing dialogue with
Gilead. The Board of Directors and management team are
committed to acting in the best interests of the Company and its
stockholders and will make a recommendation in due course with
regards to Gilead's nominees."
"Consistent with Landauer's commitment to maintaining a highly
qualified, independent Board, the Company recently appointed
Teri Fontenot as a new, independent
director and appointed current member, William Dempsey, to the role of Lead Independent
Director, replacing Robert Cronin
who will retire at the 2017 Annual Meeting. The Company also
announced Michael Leatherman's
decision to step down from the role of Executive Chairman also at
that meeting, with Mr. Dempsey assuming the position of
non-executive Chairman at that time. The Board regularly
evaluates potential director candidates to ensure it has the right
skills and expertise to guide Landauer in developing and
implementing its clear strategic plan to drive profitability and
stockholder value."
The Board will present its recommendation regarding director
nominees in Landauer's definitive proxy statement and other
materials, to be filed with the Securities and Exchange Commission
and made available to all stockholders eligible to vote at the 2017
Annual Meeting.
About Landauer
Landauer is a leading global provider of technical and
analytical services to determine occupational and environmental
radiation exposure, as well as the leading domestic provider of
outsourced medical physics services. For more than 50 years, the
Company has provided complete radiation dosimetry services to
hospitals, medical and dental offices, universities, national
laboratories, nuclear facilities and other industries in which
radiation poses a potential threat to employees. Landauer's
services include the manufacture of various types of radiation
detection monitors, the distribution and collection of the monitors
to and from customers, and the analysis and reporting of exposure
findings. The Company provides its dosimetry services to
approximately 1.8 million individuals globally. In addition,
through its Medical Physics segment, the Company provides
therapeutic and imaging physics services to the medical physics
community. For information about Landauer, please visit their
website at http://www.landauer.com.
Additional Information and Where to Find It
This press release may be deemed to be solicitation material in
connection with the matters to be considered at the 2017 annual
meeting (the "2017 Annual Meeting") of stockholders of Landauer,
Inc. ("Landauer" or the "Company"). The Company intends to file a
proxy statement and a WHITE proxy card with the U.S.
Securities and Exchange Commission (the "SEC") in connection with
any such solicitation of proxies from Landauer stockholders.
LANDAUER STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ ANY SUCH
PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO)
WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Stockholders will be able to obtain any proxy
statement, any amendments or supplements thereto and other
documents filed by the Company with the SEC for no charge at the
SEC's website at www.sec.gov. Copies will also be available at no
charge by writing to the Company at 2 Science Road, Glenwood, Illinois 60425, Attention: Corporate
Secretary.
Participants in the Solicitation
The Company and its directors and executive officers may be
deemed to be participants in the solicitation of proxies from the
Company's stockholders in connection with the matters to be
considered at the 2017 Annual Meeting. Investors may obtain
information regarding the Company and its directors and executive
officers in the Company's Annual Report on Form 10-K for the fiscal
year ended September 30, 2016, which
was filed with the SEC on December 14,
2016, and the Company's definitive proxy statement for its
2016 annual meeting of stockholders (the "2016 Annual Meeting"),
which was filed with the SEC on January 12,
2016. To the extent holdings of Landauer securities by the
Company's directors or executive officers have changed since the
amounts disclosed in the definitive proxy statement for the 2016
Annual Meeting, such changes have been or will be reflected on
Initial Statements of Beneficial Ownership on Form 3 and Statements
of Change in Beneficial Ownership on Form 4 filed with the SEC.
More detailed information regarding the identity of potential
participants in the solicitation, and their direct or indirect
interests, by security holdings or otherwise, will be set forth in
the proxy statement and other materials to be filed with the SEC in
connection with the 2017 Annual Meeting.
For the latest news releases and other corporate documents on
Landauer, Inc., visit www.landauer.com
For Further Information Contact:
Michael DeGraff
Sard Verbinnen & Co
Phone: 312.895.4734
Email: mdegraff@sardverb.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/landauer-inc-comments-on-gileads-nomination-of-directors-300381594.html
SOURCE Landauer, Inc.